|The Genetics Company, Inc., Schlieren (Switzerland)
The Genetics Company was founded in Zurich (Switzerland) in July 1998, as a joint spin-off between the University of Zurich and the Swiss Institute for Experimental Cancer Research (ISREC). In December 2002, the Company acquired key assets from CallistoGen AG in Berlin, Germany, including small molecule hit series against Alzheimer's disease. This transaction was complemented by the acquisition of German Alzheimer’s disease specialist, Abeta GmbH, in 2003, which further fortified the company’s Alzheimer’s program and established a platform for the development and marketing of diagnostic opportunities.
The Company closed its operations after selling the Alzheimer diagnostics business end of 2009. The Genetics Company was liquidated by 2012 and collected and cancelled its shares in October 2013.